BDX
Becton Dickinson and Company
NYSE: BDX · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$144.17
-1.47% today
Updated 2026-05-05
Market cap
$42.47B
P/E ratio
24.40
P/S ratio
1.94x
EPS (TTM)
$6.12
Dividend yield
2.80%
52W range
$125 – $186
Volume
2.7M
WallStSmart proprietary scores
63
out of 100
Grade: C+
Hold
Investment rating
5.3
Growth
C+5.5
Quality
C+5.5
Profitability
C+6.7
Valuation
B6/9
Piotroski F-Score
Moderate
1.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →198 stocks currently score above 75
Price targets
Analyst target
$191.46
+32.81%
12-Month target
$156.38
+8.47%
Intrinsic (DCF)
$242.22
Margin of safety
+25.43%
1 Strong Buy4 Buy9 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $549.00M — positive
+ 25.43% below intrinsic value
Risks
- Altman Z 1.49 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $18.87B | $19.37B | $20.18B | $21.84B | $21.92B | $19.5B |
| Net income | $1.78B | $1.48B | $1.71B | $1.68B | $382.00M | — |
| EPS | — | — | — | — | $6.12 | $12.57 |
| Free cash flow | $1.66B | $2.12B | $3.07B | $2.67B | $549.00M | — |
| Profit margin | 9.43% | 7.66% | 8.45% | 7.68% | 8.01% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-27 | FELD, MICHAEL | Sale | 74 | $151.94 |
| 2026-04-06 | NEAL, SHANA CAROL | Sale | 1,146 | — |
| 2026-03-26 | FELD, MICHAEL | Sale | 75 | $156.83 |
Peer comparison
Smart narrative
Becton Dickinson and Company trades at $144.17. representing a P/E of 24.40x trailing earnings. Our Smart Value Score of 63/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 1.49, it sits in the distress. TTM revenue stands at $21.92B. with profit margins at 8.01%. Our DCF model estimates intrinsic value at $242.22.
Frequently asked questions
What is Becton Dickinson and Company's stock price?
Becton Dickinson and Company (BDX) trades at $144.17.
Is Becton Dickinson and Company overvalued?
Smart Value Score 63/100 (Grade C+, Hold). DCF value $242.22.
What is the price target of Becton Dickinson and Company (BDX)?
The analyst target price is $191.46, representing +32.8% upside from the current price of $144.17.
What is the intrinsic value of Becton Dickinson and Company (BDX)?
Based on our DCF model, intrinsic value is $242.22, a +25.4% margin of safety versus $144.17.
What is the future stock price of BDX by 2030?
Our research-backed model estimates Becton Dickinson and Company could reach $803.45 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Becton Dickinson and Company's revenue?
TTM revenue is $21.92B.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
1.49 — distress.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio1.94x
ROE6.96%
Beta0.35
50D MA$160.63
200D MA$154.25
Shares out0.28B
Float0.28B
Short ratio—
Avg volume2.7M
Performance
1 week-3.58%
1 month-6.70%
3 months-30.19%
YTD-25.71%
1 year—
3 years—
5 years—